Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 2.950
+0.060 (2.08%)
Apr 24, 2026, 5:29 PM CET
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 311.27 million as of April 24, 2026. Its market cap has increased by 548.94% in one year.
Market Cap
311.27M
Enterprise Value
184.57M
Revenue
167.17M
Ranking
n/a
PE Ratio
3.01
Stock Price
2.95
Market Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 311.27M, an increase of 398.08%. That is a compound annual growth rate of 15.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 23, 2026 | 304.94M | 96.60% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Oncopeptides AB | 537.59M |
| Corline Biomedical AB | 412.38M |
| Ascelia Pharma AB | 409.79M |
| Intervacc AB | 398.07M |
| Bio-Works Technologies AB | 313.19M |
| Mendus AB | 300.97M |
| Xintela AB | 248.91M |
| Isofol Medical AB | 227.87M |